The CT2 Study examined the feasibility, acceptability, effectiveness and cost-effectiveness of a community-based testing and treatment program for hepatitis C (HCV).
This study aimed to assess the feasibility, acceptability, effectiveness, and cost-effectiveness of decentralized community-based POC testing and DAA therapy for hepatitis C among people who inject drugs and the general population in Yangon, Myanmar.
This was a feasibility study with two sites:
January 2019–September 2020.
The study protocol, site-specific informed consent forms, recruitment materials, as well as any subsequent modifications, are approved by Department of Medical Research Institutional Review Board in Myanmar and Alfred Ethics Committee in Melbourne.
Written informed consent was obtained from every study participant.
The results was submitted for publication in peer-reviewed journals and abstracts submitted for relevant conference presentations. No identifying information from study participants was included in any publications, reports or presentations. Results presented only contained aggregate data.
The results of this study informed any potential scale-up of community-based primary care provision of hepatitis C services in Myanmar and other resource-constrained settings.
Results from the CT2 Study were presented at the EASL ILC Virtual Event in August 2020. The summary findings were presented to key stakeholders at the dissemination workshop in October 2020. The Summary Report is now available online on this page.
Unitaid through the Foundation of Innovative and New Diagnostic (FIND)